Innovative Bispecific Nanobody Targeting IGF1R and TSHR for Autoimmune Disease Therapy

VHH-P281 is a bispecific, humanized nanobody fusion construct targeting insulin like growth factor 1 receptor (IGF1R) and thyroid stimulating hormone receptor (TSHR). This novel agent integrates advanced molecular design to simultaneously engage IGF1R and TSHR, two validated therapeutic targets implicated in the pathogenesis of autoimmune diseases. Currently at the Biological Testing stage, VHH-P281 demonstrates strong potential as a next-generation therapeutic option for addressing unmet clinical needs in the treatment of autoimmune diseases by leveraging the specificity and modularity of nanobody engineering.

Licensing Opportunity

VHH-P281 is available for out-licensing and strategic collaborations. We welcome inquiries from partners interested in advancing this bispecific nanobody asset for autoimmune disease therapeutics.

Development Phase

Modality

VHH-P281 is engineered as a bispecific antibody fusion protein composed of a humanized single-domain antibody (nanobody) targeting IGF1R, fused to a human IgG1 Fc fragment incorporating S228D and I332E mutations for enhanced effector function. This is further linked via (G4S)3 flexible linker to a humanized VHH directed against TSHR, facilitating dual antigen engagement. The compact, single-domain nanobody elements confer excellent tissue penetration and stability, essential for modulating pathological immune responses in autoimmune disease. Production in Chinese hamster ovary cells ensures compatibility with established biomanufacturing processes. This molecular approach provides distinct pharmacological advantages for addressing the complex, multi-factorial nature of autoimmune conditions.

Target

IGF1R and TSHR are membrane-associated receptors with distinct yet complementary roles in cellular signaling. IGF1R, a tyrosine kinase receptor, is broadly expressed in various tissues and modulates cell growth, differentiation, and survival, with dysregulation linked to immune activation in autoimmune disorders. TSHR is predominantly found in thyroid tissues and is a key regulator of thyroid function, commonly implicated in autoimmune thyroid diseases. Targeting IGF1R and TSHR offers a rational strategy for modulating aberrant immune signaling cascades critical to autoimmune disease progression. VHH-P281's dual targeting of IGF1R and TSHR positions it at the forefront of precision immunomodulation, maximizing therapeutic impact through the concurrent blockade of these pivotal receptors. The strategic engagement of both IGF1R and TSHR enhances the asset's value proposition for the autoimmune disease market.

Mechanism of Action

VHH-P281 exerts its therapeutic effects through simultaneous binding and inhibition of IGF1R and TSHR on target cells. By modulating these key signal transduction receptors, VHH-P281 disrupts pathological cellular communication underlying autoimmune responses. The bispecific nanobody format enables the selective recognition and blockade of IGF1R and TSHR, leading to attenuation of aberrant immune activity and downstream inflammation. This dual signal pathway modulation has the potential to restore immune homeostasis without broad immunosuppression. Furthermore, the nanobody platform is inherently adaptable for modular engineering, supporting expansions such as antibody-drug conjugates or further multivalent constructs for targeted immune regulation in diverse autoimmune indications.

Autoimmune Disease

Autoimmune diseases represent a heterogeneous group of chronic conditions characterized by dysregulated immune responses against self-antigens, resulting in progressive tissue and organ damage. These disorders affect millions of individuals worldwide and are associated with significant morbidity and reduced quality of life. Current therapeutic approaches, including immunosuppressive agents, chemical therapies, and emerging targeted treatments, provide symptomatic relief but are often limited by side effects, lack of specificity, and incomplete disease control. Many patients continue to experience refractory disease and flare-ups despite available options, highlighting a critical need for more precise and durable treatments. By selectively modulating IGF1R and TSHR pathways, VHH-P281 addresses key drivers of autoimmunity and offers the prospect of targeted intervention with reduced systemic immunosuppression. This mechanistically differentiated approach positions VHH-P281 as a promising candidate for advancing care in the autoimmune disease field.